Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 21266959)


Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL.

Mol Ther. 2011 Apr;19(4):650-7. doi: 10.1038/mt.2010.312. Epub 2011 Jan 25.


Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.

Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL, Thorne SH.

Neoplasia. 2012 Dec;14(12):1115-21.


Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH.

Mol Ther. 2013 Mar;21(3):620-8. doi: 10.1038/mt.2012.257. Epub 2012 Dec 11.


Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH.

PLoS Med. 2007 Dec;4(12):e353.


Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice.

Chen NG, Yu YA, Zhang Q, Szalay AA.

J Transl Med. 2011 Sep 27;9:164. doi: 10.1186/1479-5876-9-164.


Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, Huang XF.

J Immunother. 2009 Feb-Mar;32(2):145-56. doi: 10.1097/CJI.0b013e318193d31e.


Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68.

Gentschev I, Müller M, Adelfinger M, Weibel S, Grummt F, Zimmermann M, Bitzer M, Heisig M, Zhang Q, Yu YA, Chen NG, Stritzker J, Lauer UM, Szalay AA.

PLoS One. 2011;6(7):e22069. doi: 10.1371/journal.pone.0022069. Epub 2011 Jul 11.


Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene.

Brader P, Kelly KJ, Chen N, Yu YA, Zhang Q, Zanzonico P, Burnazi EM, Ghani RE, Serganova I, Hricak H, Szalay AA, Fong Y, Blasberg RG.

Clin Cancer Res. 2009 Jun 1;15(11):3791-801. doi: 10.1158/1078-0432.CCR-08-3236. Epub 2009 May 26.


A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.

Haddad D, Chen N, Zhang Q, Chen CH, Yu YA, Gonzalez L, Aguilar J, Li P, Wong J, Szalay AA, Fong Y.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S665-74. doi: 10.1245/s10434-011-2198-x. Epub 2012 Jan 19.


Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.

Flanagan K, Glover RT, Hörig H, Yang W, Kaufman HL.

Vaccine. 2004 Jul 29;22(21-22):2894-903.


Ex vivo infection of live tissue with oncolytic viruses.

Diallo JS, Roy D, Abdelbary H, De Silva N, Bell JC.

J Vis Exp. 2011 Jun 25;(52). pii: 2854. doi: 10.3791/2854.


A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.

Yang S, Guo ZS, O'Malley ME, Yin X, Zeh HJ, Bartlett DL.

Gene Ther. 2007 Apr;14(8):638-47. Epub 2007 Feb 1.


Combination of viral oncolysis and tumor-specific immunity to control established tumors.

Chuang CM, Monie A, Wu A, Pai SI, Hung CF.

Clin Cancer Res. 2009 Jul 15;15(14):4581-8. doi: 10.1158/1078-0432.CCR-08-2685. Epub 2009 Jul 7.


Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.

Guse K, Sloniecka M, Diaconu I, Ottolino-Perry K, Tang N, Ng C, Le Boeuf F, Bell JC, McCart JA, Ristimäki A, Pesonen S, Cerullo V, Hemminki A.

J Virol. 2010 Jan;84(2):856-66. doi: 10.1128/JVI.00692-09. Epub 2009 Nov 11.


Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma.

Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U, Weibel S, Chen NG, Yu YA, Zhang Q, Heisig M, Thamm D, Stritzker J, Macneill A, Szalay AA.

PLoS One. 2012;7(5):e37239. doi: 10.1371/journal.pone.0037239. Epub 2012 May 15.


A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.

Tysome JR, Li X, Wang S, Wang P, Gao D, Du P, Chen D, Gangeswaran R, Chard LS, Yuan M, Alusi G, Lemoine NR, Wang Y.

Clin Cancer Res. 2012 Dec 15;18(24):6679-89. doi: 10.1158/1078-0432.CCR-12-0979. Epub 2012 Oct 22.


MicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacy.

Hikichi M, Kidokoro M, Haraguchi T, Iba H, Shida H, Tahara H, Nakamura T.

Mol Ther. 2011 Jun;19(6):1107-15. doi: 10.1038/mt.2011.36. Epub 2011 Mar 8.


Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.

Gentschev I, Donat U, Hofmann E, Weibel S, Adelfinger M, Raab V, Heisig M, Chen N, Yu YA, Stritzker J, Szalay AA.

J Biomed Biotechnol. 2010;2010:489759. doi: 10.1155/2010/489759. Epub 2010 Apr 1.


Synergistic interaction between oncolytic viruses augments tumor killing.

Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, Parato K, Atkins H, Kirn D, Bell JC.

Mol Ther. 2010 May;18(5):888-95. doi: 10.1038/mt.2010.44. Epub 2010 Mar 16.


Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection.

Weibel S, Raab V, Yu YA, Worschech A, Wang E, Marincola FM, Szalay AA.

BMC Cancer. 2011 Feb 14;11:68. doi: 10.1186/1471-2407-11-68.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk